Brain Navi achieves U.S. FDA approval for neurosurgical robot NaoTrac

Brain Navi achieves U.S. FDA approval for neurosurgical robot NaoTrac

ZHUBEI CITY, June 17, 2025 /PRNewswire/ -- Brain Navi Biotechnology, a medical robotics company founded in 2015 in Taiwan by surgeon and serial entrepreneur Jerry Chen, has reached another major milestone. Following previous approvals from the...

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful...

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg The FDA previously approved STEQEYMA ® 45mg/0.5mL,...

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired...

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ -- ZEISS...

menu
menu